Canon Medical Research Europe, based in Edinburgh, Scotland, was awarded $180,000 to develop an artificial intelligence (AI)-based medical imaging technology prototype that can recognize, assess and measure asbestos-related cancer tumors, according to a report published Aug. 6 by Scottish Business Insider.
The funding was distributed by the Scottish Funding Council (SFC) under the Cancer Innovation Challenge (CIC), which aims to encourage innovation centers in Scotland to work together to help the country become a world leader in cancer care, according to the SFC website.
“Malignant Pleural Mesothelioma is a terrible condition for those that are unfortunate enough to suffer from it, and we believe that an automated assessment method using AI would be a major advance in fighting this disease and, potentially, other forms of lung cancer,” Ken Sutherland, president of Canon Medical Europe, told Scottish Business Insider. “The funding from CIC is critical to developing this ground-breaking tool.”
Canon Medical’s research team will be led by Kevin Blyth, MD, from the department of respiratory medicine at NHS Greater Glasglow and Clyde, to develop the prototype, according to the article.
“MPM is an exceptionally challenging cancer to start with, but the possibilities are enormous using Canon Medical’s technology our clinical and research input,” Blyth said. “While it is an ambitious project we are positive that whatever we learn will be valuable for advancing medical knowledge and taking us towards a world in which treatments are increasingly tailored, affordable and successful.”
See Scottish Business Insider’s entire article below: